Featured Research

from universities, journals, and other organizations

How Body Determines Optimal Amount Of Germ-fighting B Cells

Date:
November 8, 2008
Source:
University of Pennsylvania School of Medicine
Summary:
Researchers can now explain how the body determines whether there are enough mature B-cells in the blood stream at any one time.

Molecular crosstalk between two B-cell surface receptors (green, Y-shaped B-cell receptor and orange cylinder-shaped BLyS receptor) balances the need to have enough B cells to drive a healthy immune response while at the same time guarding against autoimmunity.
Credit: Michael P. Cancro, PhD, University of Pennsylvania School of Medicine

Researchers at the University of Pennsylvania School of Medicine can now explain how the body determines whether there are enough mature B-cells in the blood stream at any one time. These are the cells that produce antibodies against germs to fight infections.

“There is a steady state number of B cells that is considered normal for humans,” says senior author Michael P. Cancro, PhD, Professor of Pathology and Laboratory Medicine. “We found that molecular crosstalk between two receptors on the surface of B cells balances the need to have enough B cells to make good immune responses, while at the same time guarding against autoimmunity.”

The B-cell crosstalk paper appeared online this week in Nature Immunology. This and other work from the Cancro lab has important implications for transplantation science and battling autoimmune diseases.

Cancro, first author Jason E. Stadanlick, a PhD student in the Cancro lab, and others found that when more of a protein called BLyS, which binds to a receptor on B-cell surfaces is circulating, more mature B cells can be kept alive. By adding more BLyS to the system, the “brakes” governing how many immature B cells are allowed to become mature B cells are relaxed. On the other hand, the body guards against autoimmune diseases such as lupus by preventing the survival of B cells via the other receptor in this equation.

The research from the Cancro lab reveals a complicated interplay between these two receptors that allows them to integrate their signals, which are at odds with one another. “One receptor sends signals to the cell nucleus that says, ‘yes stay alive, the body needs more B cells,’ while the other says ‘wait a minute, be careful which B cells are allowed to live.’”

The Cancro lab also described in a recentProceedings of the National Academy of Sciences(PNAS) paper that if BLyS is neutralized, most B cells die, but the ones in charge of remembering what the body has already been vaccinated against or has been exposed to, remain alive.

Together, these findings should eventually lead to interventions that alter or adjust B cell behavior in the prevention, diagnosis, and treatment of autoimmune diseases.

The research described in the Nature Immunology paper was funded in part by the National Institute of Allergy and Infectious Disease and the National Institute on Aging. The research described in the PNAS paper was funded in part by a sponsored research agreement with Human Genome Sciences, Inc.


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of Pennsylvania School of Medicine. "How Body Determines Optimal Amount Of Germ-fighting B Cells." ScienceDaily. ScienceDaily, 8 November 2008. <www.sciencedaily.com/releases/2008/11/081104132904.htm>.
University of Pennsylvania School of Medicine. (2008, November 8). How Body Determines Optimal Amount Of Germ-fighting B Cells. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/11/081104132904.htm
University of Pennsylvania School of Medicine. "How Body Determines Optimal Amount Of Germ-fighting B Cells." ScienceDaily. www.sciencedaily.com/releases/2008/11/081104132904.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins